RxDoctor Payments Data

Magaly Sotres, MD

Family Medicine · Gretna, LANPI 1346739083

Payments from drug & device makers

$1,085in general payments, 2019–2025

Across 38 payments — averaging $28.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$624
  • Coloplast$111
  • Otsuka America Pharmaceutical, Inc.$66
  • Baxter Healthcare$65
  • Novo Nordisk$53
  • BD$37
  • plus $129 from 5 others

What the payments were for

  • Consulting fees$656%
  • Food & beverage$1,02094%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,085 in reported general payments places this provider in the 55th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$8,257
Medicare patients
24
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin33$52,984
MounjaroTirzepatide32$39,481
OzempicSemaglutide28$33,614
JanuviaSitagliptin Phosphate21$19,728
ProliaDenosumab11$18,770
FarxigaDapagliflozin Propanediol11$14,336
EliquisApixaban11$12,125
Atorvastatin Calcium134$787
Omeprazole60$716
Rosuvastatin Calcium67$650
Albuterol Sulfate HfaAlbuterol Sulfate17$610
Gabapentin46$606
Fluticasone Propionate38$595
Valsartan11$489
Mirtazapine20$401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$18$52,98433 claims
Lilly USA, LLCMounjaro$624$39,48132 claims
Novo NordiskOzempic$53$33,61428 claims
AmgenProlia$16$18,77011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Gretna

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →